

HEMO ORGANIC LIMITED

CIN: - L24231GJ1992PLC018224

Address: - 8-A, Gulnar, Chinar - Gulnar Appt. V V Nagar Road Anand -388001

Email ID: -drdineshpatel@rediffmail.com, Website: - www.hemoorganicltd.com

Date: August 09, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Submission of Unaudited Financial Result of the Company for the quarter ended on June 30, 2022 along with Limited Review Report.

Ref: Hemo Organic Limited (Security ID: HEMORGANIC, Security Code: 524590)


In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

1. Unaudited Financial Results for the quarter ended on June 30, 2022;
2. Limited Review Report.

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking you

For, Hemo Organic Limited



Dr. Dinesh Patel
Chairman and Managing Director
DIN 00481641
Place: Anand



HEMO ORGANIC LIMITED

CIN: L24231GJ1992PLC018224

Registered Office: 8-A, GULNAR, CHINAR - GULNAR APPT. V V NAGAR ROAD ANAND GJ 388001

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30th June, 2022

(Rs. In lakh)

Particulars	Quarter ended on			Year Ended on
	30-06-22	31-03-22	30-06-21	31-03-22
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1 Revenue from operations	-	-	-	0.68
2 Other income	-	-	-	-
3 Total Income (1+2)	-	-	-	0.68
Expenses				
a. Purchases	-	-	2.39	2.39
b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	2.39	(1.46)
c. Employee benefits expense	-	0.36	1.08	3.60
d. Finance costs	-	0.01	-	0.01
e. Depreciation & amortisation expense	-	-	-	-
f. Other expenses	-	0.37	0.31	2.38
Total Expenses	-	0.74	1.39	6.92
5 Profit / (Loss) before exceptional items and tax (3-4)	-	(0.74)	(1.39)	(6.24)
6 Exceptional items	-	-	-	-
7 Profit / (Loss) before tax (5+6)	-	(0.74)	(1.39)	(6.24)
8 Tax expense:				
Current tax	-	-	-	-
Deferred tax	-	-	-	-
9 Profit (Loss) for the period from continuing operations (7-8)	-	(0.74)	(1.39)	(6.24)
10 Profit/(loss) from discontinuing operations before Tax	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-
13 Profit / (Loss) for the period (9+12)	-	(0.74)	(1.39)	(6.24)
14 Other Comprehensive Income				
<i>Items that will not be reclassified subsequently to profit or loss</i>	-	-	-	-
Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
<i>Items that will be reclassified subsequently to profit or loss</i>				
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Other Comprehensive Income, net of tax	-	-	-	-

15	Total Comprehensive Income for the period (13+14)	-	(0.74)	(1.39)	(6.24)
16	Earnings Per Share of Rs. 10/- each				
	(for continuing operations)				
	- Basic	-	0.02)	(0.04)	(0.18)
	- Diluted	-	0.02)	(0.04)	(0.18)
17	Earnings Per Share of Rs. 10/- each				
	(for discontinued operations)				
	- Basic	-	-	-	-
	- Diluted	-	-	-	-
18	Earnings Per Share of Rs. 10/- each				
	(for discontinued & continuing operations)				
	- Basic	-	0.02)	(0.04)	(0.18)
	- Diluted	-	0.02)	(0.04)	(0.18)



For, Hemo Organic Limited

KMP

Dr. Dinesh Patel
Chairman and Managing Director
DIN 00481641

Place: Ahmedabad
Date : 09/08/2022

Notes:

1

The above standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on August 09, 2022.

2 The financial results of the company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the companies Act, 2013 read with relevant rules there under and in terms with regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) regulations 2015 and SEBI circular dated 5th July 2016.

3 The statutory Auditors of the company have carried out a "Limited Review" of the above result as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The IND AS compliant corresponding figures of the previous year have not been subject to review, however the company's management has exercised necessary due diligence to ensure that

such financial results provide true and fair view.

4 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities if any.

5

Previous period figures have been reclassified / regrouped wherever considered necessary to confirm to the current period figures.



For, Hemo Organic Limited

Dr. Dinesh Patel

Place: Ahmedabad Chairman and Managing Director Date : 09/08/2022 DIN 00481641

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE
FINANCIAL RESULTS OF HEMO ORGANIC LIMITED PURSUANT TO THE REGULATION
33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS)
REGULATIONS, 2015 FOR THE PERIOD ENDED 30th JUNE, 2022**

To,

The Board of Directors,
Hemo Organic Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Hemo Organic Limited for the quarter ended 30th June, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FCA/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, except **as specified in Qualified Opinion para**, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Emphasis on Matter:

1. The closing stock has been calculated and certified by management only and we have not been provided with the basis of calculation.
2. The Company has not charged depreciation on the fixed assets during the year and accordingly provision of Indian Accounting Standards relating to depreciation and Deferred Tax Asset / Liabilities have not been followed. The management represented that the amount of depreciation being negligible the same has been not been incorporated.

Qualified Opinion:

1. We have not been provided with the balance confirmation or any other details for the trade receivable, trade payable & Loans and Advances receivables/payables shown in the books of accounts & in the absence of the same we are unable to confirm the balance and nature of the transaction.
2. We have not been able to verify the transactional documents relating bank statements. Four out of five account are not shown to us for verification. According to the management, the other accounts are dormant and therefore the same have not been collected from bank.

Date : 09/08/2022
Place: Ahmedabad
UDIN: 22133926AOQFLV47

For, M A A K & Associates
(Chartered Accountants)
F.R.N.: 135024W



CA Marmik Shah
(Partner)
Mem. No.:133926